Trial · NCT01269125
GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.
NCT01269125, Not applicable, Completed, University of Ioannina; results first posted 2013-07-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles. Trials, record NCT01269125. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01269125
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.
- NCT number
- NCT01269125
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 180 participants, actual
- Lead sponsor
- University of Ioannina
- Conditions
- Endometriosis, Infertility
- Interventions
- Leuprolide, IVF
- First posted
- 2011-01-04
- Last updated
- 2013-07-30
- Results first posted
- 2013-07-24
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Pregnancy Rate | June 2004-August 2010 | Clinical pregnancy was confirmed by observing fetal cardiac activity on transvaginal ultrasound four weeks after a positive pregnancy test. |
| Primary | Embryo Quality (the Percentage of Grade 1 Embryos Per Participant). | June 2004-August 2010 | Embryo development was evaluated 2 days after oocyte pick-up. The number of blastomeres and the proportion of embryo volume occupied by fragments were used for the evaluation. Embryos with \< 10%, \< 10-20%, \< 20-30% and \>30% fragments were estimated as grade 1,2,3 and 4, respectively. |
| Primary | Fertilization Rate (Percentage of Fertilized Oocytes). | June 2004-August 2010 | The fertilization rate was estimated for every woman 24 hours after oocyte retrieval |
| Primary | Clinical Pregnancy Rate | 4 weeks after a positive pregnancy test | Clinical pregnancy rate was confirmed by observing fetal cardiac activity on transvaginal ultrasound four weeks after a positive pregnancy test. |
| Secondary | Follicular Fluid's TNF-a Concentration. | June 2004-August 2010 | TNF-a was measured in the FF of all women (secondary outcome measures). To prevent any cytokine alterations, only blood-free samples were used. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Pregnancy Rate | June 2004-August 2010 | The study period was seven years. Practical issues such as, no more funds for measuring cytokines, my transportation to different University stopped this study before reaching adequate power. The flow of the participants in our Department was low. | percentage | MEAN |
| PRIMARY | Embryo Quality (the Percentage of Grade 1 Embryos Per Participant). | June 2004-August 2010 | Percentage of grade 1 embryos | MEAN | |
| PRIMARY | Fertilization Rate (Percentage of Fertilized Oocytes). | June 2004-August 2010 | percentage | MEAN | |
| SECONDARY | Follicular Fluid's TNF-a Concentration. | June 2004-August 2010 | pg/ml | MEAN | |
| PRIMARY | Clinical Pregnancy Rate | 4 weeks after a positive pregnancy test | In order to handle the problem of small sample size bootstrap techniques are used. Ader et al recommend bootstrap procedures(a) distribution is complicated or unknown, (b) a small sample is available. Finally, the bootstrap distribution has been used in order to calculate all the confidence intervals. | Percentage | MEAN |
Source ClinicalTrials.gov
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Pregnancy Rate | Endometriosis, GnRH-a Treatment, IVF | 28.3 | 95% Confidence Interval 17 to 43 | percentage | |
| Clinical Pregnancy Rate | Endometriosis, IVF | 25.4 | 95% Confidence Interval 15 to 39 | percentage | |
| Clinical Pregnancy Rate | Tubal Infertility, IVF | 33.3 | 95% Confidence Interval 17 to 41 | percentage | |
| Embryo Quality (the Percentage of Grade 1 Embryos Per Participant). | Endometriosis, GnRH-a Treatment, IVF | 25.5 | 95% Confidence Interval 23.25 to 26.94 | Percentage of grade 1 embryos | |
| Embryo Quality (the Percentage of Grade 1 Embryos Per Participant). | Endometriosis, IVF | 22.6 | 95% Confidence Interval 20.21 to 33.85 | Percentage of grade 1 embryos | |
| Embryo Quality (the Percentage of Grade 1 Embryos Per Participant). | Tubal Infertility, IVF | 27.0 | 95% Confidence Interval 18.51 to 29.07 | Percentage of grade 1 embryos | |
| Fertilization Rate (Percentage of Fertilized Oocytes). | Endometriosis, GnRH-a Treatment, IVF | 73.7 | 95% Confidence Interval 72.90 to 78.87 | percentage | |
| Fertilization Rate (Percentage of Fertilized Oocytes). | Endometriosis, IVF | 62.7 | 95% Confidence Interval 57.03 to 66.08 | percentage | |
| Fertilization Rate (Percentage of Fertilized Oocytes). | Tubal Infertility, IVF | 75.7 | 95% Confidence Interval 74.96 to 77.24 | percentage | |
| Follicular Fluid's TNF-a Concentration. | Endometriosis, GnRH-a Treatment, IVF | TNF-a | 21.4 | Standard Deviation 6.7 | pg/ml |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Endometriosis, GnRH-a Treatment, IVF | 60 | |
| Overall Study | STARTED | Endometriosis, IVF | 60 | |
| Overall Study | STARTED | Tubal Infertility, IVF | 60 | |
| Overall Study | COMPLETED | Endometriosis, GnRH-a Treatment, IVF | 53 | |
| Overall Study | COMPLETED | Endometriosis, IVF | 55 | |
| Overall Study | COMPLETED | Tubal Infertility, IVF | 60 | |
| Overall Study | NOT COMPLETED | Endometriosis, GnRH-a Treatment, IVF | 7 | |
| Overall Study | NOT COMPLETED | Endometriosis, IVF | 5 | |
| Overall Study | NOT COMPLETED | Tubal Infertility, IVF | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Premature luteinization | Reproductive system and breast disorders | Endometriosis, GnRH-a Treatment, IVF | 1 | 56 | 1 |
| other | Premature luteinization | Reproductive system and breast disorders | Endometriosis, IVF | 1 | 60 | 1 |
| other | Premature luteinization | Reproductive system and breast disorders | Tubal Infertility, IVF | 0 | 60 | 0 |
| serious | Ovarian hyperstimulation syndrome | Reproductive system and breast disorders | Endometriosis, GnRH-a Treatment, IVF | 2 | 60 | 2 |
| serious | Ovarian hyperstimulation syndrome | Reproductive system and breast disorders | Endometriosis, IVF | 4 | 60 | 4 |
| serious | Ovarian hyperstimulation syndrome | Reproductive system and breast disorders | Tubal Infertility, IVF | 0 | 60 | 0 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Endometriosis, GnRH-a Treatment, IVF | ||
| Total, all-cause mortality | Endometriosis, IVF | ||
| Total, all-cause mortality | Tubal Infertility, IVF | ||
| Total, other adverse events | Endometriosis, GnRH-a Treatment, IVF | 1 | 56 |
| Total, other adverse events | Endometriosis, IVF | 1 | 60 |
| Total, other adverse events | Tubal Infertility, IVF | 0 | 60 |
| Total, serious adverse events | Endometriosis, GnRH-a Treatment, IVF | 2 | 60 |
| Total, serious adverse events | Endometriosis, IVF | 4 | 60 |
| Total, serious adverse events | Tubal Infertility, IVF | 0 | 60 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01269125
GET https://conductscience.org/api/trials/v1/NCT01269125/results?page=2